Newsletter

The Patent Trial and Appeal Board has denied Apple's petition for inter partes review of a Uniloc patent covering technology for upgrading electronic devices

Teva Pharmaceutical USA Inc. has inked a deal to resolve a patent case from Collegium Pharmaceutical Inc. over Teva's attempt to get a generic alternative to Collegium's Xtampza ER painkiller approved

Federal Circuit affirmed under Rule 36 the decision by the District Court of Nevada (Du, J.) in March that the claims asserted by Amarin Pharma against West-Ward Pharmaceuticals Inter national Ltd.

In a unanimous decision, the Federal Circuit has ruled U.S. Patent No. 4,405,829 invalid un- der 35 U.S.C. § 101, finding the claimed invention directed to an abstract idea.

Genetic instability has long been recognized as a hallmark of oncogenesis and tumor progres- sion. The phenomenon was first identified cytogenetically, most famously by the

Chevron has gotten a Texas jury's award of $1.1 million boosted to a final judgment of more than $15.6 million against a company that infringed its trademark to dupe other companies into doing business with it.

Ever since the Supreme Court's decision in Dickinson v. Zurko, patent applicants (and with the advent of inter partes review proceedings before the Patent Trial and Appeal Board, patentees) have found

In 2014's Alice Corp. v. CLS Bank Int'l case, Justice Thomas famously wrote, "we need not labor to delimit the precise contours of the 'abstract ideas' category in this case." Instead,

Federal Circuit issued a per curiam Order in NZNP Finance Ltd. v. Actavis Laboratories UT, Inc., denying a petition for rehearing en banc filed by Plaintiffs-Appellants HZNP Finance Ltd. and Horizon Therapeutics USA, Inc.

The Federal Circuit issued a per curiam Order in BioDelivery Sciences International, Inc. v. Aquestive Therapeutics, Inc., denying a petition for a panel rehearing or rehearing en banc filed by Appellant BioDelivery Sciences International, Inc. Judge